Triple agonist: difference between revisions
Diff·revision 8 → 9·17:26, 5 Jan 2025
Difference between revision 8 and revision 9 of Triple agonist. 5 lines changed; the page grew by 574 bytes.
| Revision 8 — 22:48, 14 Dec 2024 CagriCass (talk) expand §Consequences of the glucagon arm 2,546 bytes ±0 | Revision 9 — 17:26, 5 Jan 2025 SchematicScout (talk) the lead claimed weekly dosing for a compound dosed daily; corrected 3,120 bytes +574 | ||
|---|---|---|---|
| 19 | Reported potency ratios are assay-dependent and are not comparable between publications, a caution that applies with more force here because three numbers are being compared rather than two.{{r|coskun2022}} | 19 | Reported potency ratios are assay-dependent and are not comparable between publications, a caution that applies with more force here because three numbers are being compared rather than two.{{r|coskun2022}} |
| 20 | 20 | ||
| + | 21 | == Consequences of the glucagon arm == | |
| + | 22 | Two observations in the phase 2 data are attributable to glucagon-receptor agonism: a dose-dependent heart-rate increase larger than that seen with GLP-1 monotherapy, and transient rises in fasting glucose at low doses in participants with diabetes.{{r|jastreboff2023}} | |
| + | 23 | ||
| + | 24 | The second is the design's predicted failure mode. At low total dose the glucagon component is not yet offset by sufficient GLP-1 agonism, so glycaemia worsens before it improves — which is why escalation schedules for these compounds are long.{{r|coskun2022}} | |
| + | 25 | ||
| 21 | == References == | 26 | == References == |
| 22 | {{reflist}} | 27 | {{reflist}} |